Page 4 - Tech Transfer News Today

/PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com) has announced today that the Tech Transfer process of SAL200, endolysin-based new...

The director of NIST’s Manufacturing Extension Partnership looks ahead to the most transformative technology taking hold in the manufacturing world.

Fitzsimons Innovation Community continues to expand on it's already massive campus in 2023 and beyond.

Frankfurt, Germany (PRWEB) November 30, 2022 -- about:blank [PharmaLex Group __title__ null]’s about:blank [Biopharma Excellence __title__ null] service line,

A drug compound attacks hard-to-treat prostate cancer on several fronts, according to a Washington University School of Medicine in St. Louis study in mice and human cells. It triggers immune cells to attack, helps the immune cells penetrate the tumor and cuts off the tumor’s ability to burn testosterone as fuel.

Attend this Lunch and Learn from noon-1 p.m. on Tuesday (Sept. 13) to meet the director and case managers and learn how the Office of Tech Transfer can help you with commercializing research.

According to a study, a single drug compound can help immune cells penetrate tumors, and cut off the tumor’s ability to burn testosterone as fuel in prostate cancer.

A single drug compound simultaneously attacks hard-to-treat prostate cancer on several fronts, according to a new study in mice and human cells.

We are pleased to announce that Ajinomatrix will be combining its data integration approach for the food and beverage industry with Hebrew University's patent-pending AI technology for modeling the relationships between recipes and taste targets licensed under Yissum, Hebrew University's Tech Transfer Company.

Ajinomatrix Licenses AI Meta-Recipe Patent & Neural Networks from Hebrew University’s Revolutionary Digital Gastronomy Laboratory (Nov 18, 2022)